Be willing to return to the center for all study-related follow up procedures, including blood collections and completion of imaging studies as required by the protocol Patients with inability to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to drug administration plan, other study procedures, and study restrictions Able to return for treatment and follow-up on the specified days Patients with inability to return for follow-up visits to assess toxicity to therapy Patients with known inability to return for follow-up visits or obtain follow-up studies required to assess for toxicity to therapy will be excluded Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy Patients who are unable to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy. Ability to attend required study visits and return for adequate follow up, as required by this protocol Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy Patients who are unable to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy; telemedicine visits are acceptable Ability to return to Duke University Medical Center for adequate follow-up, as required by this protocol Agree to follow protocol required evaluations Patients must be able to return to surgical facility for and/or day (+/- days) follow up appointment Patients who in the opinion of the investigator are unwilling or unable to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to device usage plan, other study procedures, and study restrictions Able to return for treatment and follow-up as specified in the protocol Ability to attend required study visits and return for adequate follow-up, as required by this protocol. Patients who in the opinion of the investigator are unwilling or unable to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to drug administration plan, other study procedures, and study restrictions Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy Patients must be willing to return to the clinic for follow-up visits Willing to return to participating medical institutions for follow-up Must agree to follow pregnancy precautions as required by protocol. Inability to Participate Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy. Ability to attend required study visits and return for adequate follow up, as required by this protocol Agree to return for all follow-up evaluations and procedures specified in the protocol Patients who in the opinion of the investigator are unwilling or unable to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to drug administration plan, other study procedures, and study restrictions Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy Willingness to return to University of Maryland Greenebaum Cancer Center (UMGCC) or other participating institutions for treatment and follow-up Subjects with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy Ability to return to Duke University Medical Center for adequate follow-up as required by this protocol Ability to provide informed consent, and to return to clinic for adequate follow-up for the period that the protocol requires The subject must be willing to return to the study center for vaccinations and study-related follow up procedures including blood and tumor collections and completion of imaging studies as required by the protocol. Must agree to follow pregnancy precautions as required by the protocol. Inability to return for follow-up visits or obtain follow-up studies required to assess toxicity and response to therapy Patients who are unable to return for follow-up visits as required by this study RECURRENT/ PROGRESSIVE DIPG (STRATUM ): Patients who in the opinion of the investigator are unwilling or unable to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to drug administration plan, other study procedures, and study restrictions NON-PROGRESSED DIPG (STRATUM ): Patients who in the opinion of the investigator are unwilling or unable to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to drug administration plan, other study procedures, and study restrictions Agreement to return for the trial required follow-up visits Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy Able to follow instructions Unable to return for follow-up visits and tests Subjects, who, in the opinion of the clinical Investigator, are able to understand this clinical investigation, cooperate with the investigational procedures and are willing to return for all the required post-treatment follow-up visits Return for follow-up visits Patients must be willing to return to National Institutes of Health (NIH) for follow-up